Hims & Hers Health IPO
Hims & Hers Health is a direct-to-consumer telehealth platform offering treatments for various health conditions including hair loss, erectile dysfunction, skincare, and mental health. The company provides online consultations with healthcare providers and delivers prescription medications directly to consumers. It represents a major player in the digital health and telemedicine space.
Key Facts
| Industry | Digital Healthcare |
| Founded | 2017 |
| Headquarters | San Francisco, CA |
| Employees | ~800 |
| Website | hims.com |
| Funding | Public company (NYSE: HIMS) via SPAC merger at $1.6B valuation |
About Hims & Hers Health
Hims & Hers Health operates a direct-to-consumer telemedicine platform that provides personalized healthcare solutions for conditions that are often stigmatized or difficult to discuss, including sexual health, mental health, dermatology, and primary care. The company's model combines online consultations with licensed healthcare providers, personalized treatment plans, and direct-to-door medication delivery. Hims & Hers has built separate brand experiences for men (Hims) and women (Hers), with marketing and product positioning tailored to each demographic's specific health concerns and preferences.
Since going public through a SPAC merger in 2021, the company has expanded beyond its original focus on erectile dysfunction and hair loss treatments to become a more comprehensive telehealth platform. Hims & Hers has demonstrated strong growth in subscriber acquisition and retention, leveraging digital marketing and a streamlined user experience to reduce barriers to healthcare access. The company's success has validated the market demand for convenient, discreet healthcare services, particularly among younger demographics who prefer digital-first healthcare interactions.
IPO Status
Hims & Hers Health went public in January 2021 through a SPAC merger with Oaktree Acquisition Corp, initially trading under the ticker symbol HIMS on the NYSE. The company began trading at around $10-12 per share following the SPAC transaction. The stock has experienced significant volatility since going public, with shares reaching highs above $25 in early 2021 before declining substantially. Since going public, the company has focused on expanding its service offerings and customer base while working toward profitability. The stock performance has been influenced by broader market sentiment toward telehealth companies and growth stocks. Investors have been watching the company's ability to scale its operations and achieve sustainable growth in the competitive direct-to-consumer healthcare market.
Competitors
Frequently Asked Questions
Does Hims & Hers Health have a stock?
Yes, Hims & Hers Health completed its IPO through a SPAC merger in January 2021. The company has been publicly traded on the NYSE under the ticker HIMS since then.
When is the Hims & Hers Health IPO date?
Hims & Hers Health already completed its public debut in January 2021 via SPAC merger. The company is currently trading on public markets.
How can I buy Hims & Hers Health stock?
You can buy Hims & Hers stock through any broker that offers NYSE-listed stocks under the ticker symbol HIMS. The stock is available for purchase during regular trading hours and through most online brokerages.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts